The Call for Opposition: Challenging the P2P and IOM Processes
In our second article on how to react to the publication of the draft P2P report, Gabby Klein provides her view of why she and a large group of advocates and patients are continuing their protest of the government’s ongoing control and manipulation of our disease via their processes...
Discuss the article on the Forums.

Johnson & Johnson Will Share Clinical Trial Data

Discussion in 'Other Health News and Research' started by MeSci, Feb 4, 2014.

  1. MeSci

    MeSci ME/CFS since 1995; activity level 6

    Cornwall, UK
    From Physician's First Watch

    Valentijn, SOC, Sean and 3 others like this.
  2. Simon


    Monmouth, UK
    Good article from the New York Times:
    Give the Data to the People -
    [OK, so not actually giving the data to the people, but giving researchers the chance to apply for the data to an independent third party - which should stop the orginal researchers from simply blocking access to those whose views they don't like.]

    The piece (written by the independent third party holding the data) adds about researchers fear over sharing eg
    Then comes the example of Medtronic, a licensced bone stimulating product that had had its original data analysis queried. The manufacturers then released all the data and Independent reviews were commissioned:
    Of course, I think of the CFS PACE trial and the reluctance to make data available to anyone because of fears the data would be 'misused'. Perhpas the PACE authors would consider releasing ALL the trial data to a third party for independent review? It could take a lot of the heat out of the situation.
    Valentijn and MeSci like this.

See more popular forum discussions.

Share This Page